ABIVAX Société Anonyme (ABVX)
NASDAQ: ABVX · Real-Time Price · USD
86.32
+2.31 (2.75%)
Sep 15, 2025, 2:23 PM EDT - Market open
ABIVAX Société Anonyme Revenue
ABIVAX Société Anonyme had revenue of 1.05M EUR in the quarter ending June 30, 2025, a decrease of -81.34%. This brings the company's revenue in the last twelve months to 6.02M, down -33.90% year-over-year. In the year 2024, ABIVAX Société Anonyme had annual revenue of 10.79M with 135.94% growth.
Revenue (ttm)
6.02M EUR
Revenue Growth
-33.90%
P/S Ratio
885.24
Revenue / Employee
87,290 EUR
Employees
69
Market Cap
6.26B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 10.79M | 6.22M | 135.94% |
Dec 31, 2023 | 4.57M | 69.00K | 1.53% |
Dec 31, 2022 | 4.51M | 302.00K | 7.19% |
Dec 31, 2021 | 4.20M | 4.19M | 29,921.43% |
Dec 31, 2020 | 14.00K | 21.00K | -300.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ABVX News
- 3 days ago - Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review - GlobeNewsWire
- 6 days ago - Abivax Presents First Half 2025 Financial Results - GlobeNewsWire
- 16 days ago - How Hedge Funds Won Big on an Obscure Drugmaker - WSJ
- 19 days ago - 2 Logical Mid-Cap Biotech Buyout Targets - Seeking Alpha
- 6 weeks ago - Abivax Announces Closing of $747.5 Million Public Offering - GlobeNewsWire
- 7 weeks ago - Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) - GlobeNewsWire
- 7 weeks ago - Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst - Seeking Alpha
- 7 weeks ago - Abivax announces trading resumption of its ordinary shares on Euronext Paris - GlobeNewsWire